Biogen Statistics
Total Valuation
Biogen has a market cap or net worth of $30.72 billion. The enterprise value is $37.79 billion.
| Market Cap | 30.72B |
| Enterprise Value | 37.79B |
Important Dates
The last earnings date was Wednesday, July 29, 2026, before market open.
| Earnings Date | Jul 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biogen has 147.75 million shares outstanding. The number of shares has increased by 1.20% in one year.
| Current Share Class | 147.75M |
| Shares Outstanding | 147.75M |
| Shares Change (YoY) | +1.20% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 0.21% |
| Owned by Institutions (%) | 97.00% |
| Float | 147.11M |
Valuation Ratios
The trailing PE ratio is 36.88 and the forward PE ratio is 15.67. Biogen's PEG ratio is 6.06.
| PE Ratio | 36.88 |
| Forward PE | 15.67 |
| PS Ratio | 3.06 |
| Forward PS | 2.93 |
| PB Ratio | 1.63 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 11.39 |
| P/OCF Ratio | 10.67 |
| PEG Ratio | 6.06 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.44, with an EV/FCF ratio of 14.02.
| EV / Earnings | 45.28 |
| EV / Sales | 3.77 |
| EV / EBITDA | 17.44 |
| EV / EBIT | 28.53 |
| EV / FCF | 14.02 |
Financial Position
The company has a current ratio of 1.87, with a Debt / Equity ratio of 0.44.
| Current Ratio | 1.87 |
| Quick Ratio | 0.94 |
| Debt / Equity | 0.44 |
| Debt / EBITDA | 3.85 |
| Debt / FCF | 3.10 |
| Interest Coverage | 4.65 |
Financial Efficiency
Return on equity (ROE) is 4.58% and return on invested capital (ROIC) is 8.86%.
| Return on Equity (ROE) | 4.58% |
| Return on Assets (ROA) | 5.21% |
| Return on Invested Capital (ROIC) | 8.86% |
| Return on Capital Employed (ROCE) | 4.70% |
| Weighted Average Cost of Capital (WACC) | 4.64% |
| Revenue Per Employee | $1.34M |
| Profits Per Employee | $111,280 |
| Employee Count | 7,500 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 0.93 |
Taxes
In the past 12 months, Biogen has paid $176.80 million in taxes.
| Income Tax | 176.80M |
| Effective Tax Rate | 17.48% |
Stock Price Statistics
The stock price has increased by +60.77% in the last 52 weeks. The beta is 0.16, so Biogen's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | +60.77% |
| 50-Day Moving Average | 201.92 |
| 200-Day Moving Average | 184.90 |
| Relative Strength Index (RSI) | 54.15 |
| Average Volume (20 Days) | 1,350,054 |
Short Selling Information
The latest short interest is 6.00 million, so 4.06% of the outstanding shares have been sold short.
| Short Interest | 6.00M |
| Short Previous Month | 5.72M |
| Short % of Shares Out | 4.06% |
| Short % of Float | 4.08% |
| Short Ratio (days to cover) | 3.87 |
Income Statement
In the last 12 months, Biogen had revenue of $10.03 billion and earned $834.60 million in profits. Earnings per share was $5.64.
| Revenue | 10.03B |
| Gross Profit | 7.85B |
| Operating Income | 2.52B |
| Pretax Income | 1.01B |
| Net Income | 834.60M |
| EBITDA | 2.17B |
| EBIT | 1.32B |
| Earnings Per Share (EPS) | $5.64 |
Balance Sheet
The company has $1.29 billion in cash and $8.36 billion in debt, with a net cash position of -$7.07 billion or -$47.85 per share.
| Cash & Cash Equivalents | 1.29B |
| Total Debt | 8.36B |
| Net Cash | -7.07B |
| Net Cash Per Share | -$47.85 |
| Equity (Book Value) | 18.85B |
| Book Value Per Share | 127.61 |
| Working Capital | 3.39B |
Cash Flow
In the last 12 months, operating cash flow was $2.88 billion and capital expenditures -$182.20 million, giving a free cash flow of $2.70 billion.
| Operating Cash Flow | 2.88B |
| Capital Expenditures | -182.20M |
| Depreciation & Amortization | 842.90M |
| Net Borrowing | 1.02B |
| Free Cash Flow | 2.70B |
| FCF Per Share | $18.25 |
Margins
Gross margin is 78.32%, with operating and profit margins of 25.09% and 8.32%.
| Gross Margin | 78.32% |
| Operating Margin | 25.09% |
| Pretax Margin | 10.09% |
| Profit Margin | 8.32% |
| EBITDA Margin | 21.62% |
| EBIT Margin | 13.21% |
| FCF Margin | 26.89% |
Dividends & Yields
Biogen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.20% |
| Shareholder Yield | -1.20% |
| Earnings Yield | 2.72% |
| FCF Yield | 8.78% |
Analyst Forecast
The average price target for Biogen is $235.32, which is 13.17% higher than the current price. The consensus rating is "Buy".
| Price Target | $235.32 |
| Price Target Difference | 13.17% |
| Analyst Consensus | Buy |
| Analyst Count | 36 |
| Revenue Growth Forecast (3Y) | 3.32% |
| EPS Growth Forecast (3Y) | 7.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on January 18, 2001. It was a forward split with a ratio of 3:1.
| Last Split Date | Jan 18, 2001 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Biogen has an Altman Z-Score of 2.73 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.73 |
| Piotroski F-Score | 4 |